MedPath

Single Arm Post-marketing Study of SC20 Colonoscope

Phase 4
Terminated
Conditions
Gentle Colonoscopy
Interventions
Device: SC20 Colonoscope
Registration Number
NCT02279836
Lead Sponsor
Invendo Medical GmbH
Brief Summary

The objective of the study is to gather post-market data regarding the performance of the invendo SC20 colonoscope in a real-world US population.

Detailed Description

The objective of the study is to expand data collection and product exposure in a controlled clinical setting and gather data regarding the performance of the Invendo SC20 colonoscope in a real-world US population. The objective of the study is to specifically monitor three points:

1. The diagnostic performance of the device including polyp and adenoma detection rates;

2. The therapeutic performance of the device (the ability of the physician to remove/biopsy identified lesions);

3. Performance of the device in a typical colonoscopy population, including patients with underlying inflammatory bowel disease (IBD), previous pelvic surgery or irradiation, obesity, diverticular disease, and previous colorectal surgery, as they present in the study population (see below C.).

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
2
Inclusion Criteria
  • Any indication for colonoscopy
  • Willing to give informed consent
  • Willing to consume 2-4 liters of bowel prep
Exclusion Criteria
  • An age younger than 18 years
  • Congestive heart failure
  • Renal insufficiency
  • Intestinal obstruction
  • Any acute life-threatening condition (in the opinion of the investigator)
  • Current pregnancy
  • Abdominal surgery in the past 6 months
  • Bleeding disorders
  • Inability to provide informed consent
  • Any other contraindication to colonoscopy (e.g. fulminant colitis or acute diverticulitis)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single arm post-marketing StudySC20 ColonoscopeSC20 Colonoscope and Colonoscopy System For Colonoscopy
Primary Outcome Measures
NameTimeMethod
1. Cecal intubation rates (visualization of the cecum by notation of landmarks and photo documentation of landmarks in every procedure)average 6 to 12 months
Secondary Outcome Measures
NameTimeMethod
2. Detection of polyps, adenomas and other lesions in all individualsaverage 6 to 12 months

Trial Locations

Locations (3)

Bellevue Hospital Center

🇺🇸

New York, New York, United States

NYU Langone Medical Center Ambulatory care

🇺🇸

New York, New York, United States

New York Presbyterian Columbia University Medical Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath